Plain-English translation of NCT07232524 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial (Phase I) testing a new medication called in patients with advanced head and neck squamous cell carcinoma and other solid tumors. The study is designed to find the right dose of this medication, understand how your body processes it, and see whether it helps shrink tumors. Researchers will carefully monitor you for side effects and signs that the treatment is working.
Head and neck cancers and other solid tumors can be difficult to treat, especially when they have spread. This medication is a new type of antibody designed to target cancer cells in a different way, and researchers want to test whether it could offer patients a new treatment option.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through a vein) during the first 2-week cycle. If you tolerate the treatment well and your cancer shows signs of responding, you may receive additional treatment cycles. Throughout the trial, you will have regular blood tests, heart monitoring, and imaging scans to check how you are responding and watch for any side effects. The study will end if your disease progresses, you experience unacceptable side effects, or for other medical reasons your doctor deems appropriate.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
China